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ABSTRACT
Objective: The objective was to study the assessment of the possible cardiotoxic effect of imatinib using echocardiography.
Methods: Prospective study included 50 patients that treated at the National Hematology Center of Al-Mustansiriya University from May 2008 to 
December 2009, echocardiography was used to measure the cardiac ejection fraction accurately, indices of ventricular ejection and relaxation and 
measurement of left ventricular internal diameter in diastole and (LVIDd) at baseline and after 12 months.
Results: 24 (41%) were men and 26 (59%) were women. Their ages ranged from 18 to 74 years, with a median age of 36.8 years. At baseline, mean EF 
was 0.63±0.057 and after 12 months; mean EF was 0.64±0.068 (p>0.05). Mean peak emptying rate at baseline was 3.23±0.5 ED/s, and after 1 year was 
3.21±0.5 ED/s (p>0.05). Time to peak filling rate at baseline was 144±26 ms, and after 1 year was 143±25 ms (p>0.05). There is a significant inverse 
trend for both LVIDd and LVID in systole (LVIDs) reduced as age increase; the female had significantly lower LVIDd and LVIDs compared to male.
Conclusion: We find no evidence of significant impairment in cardiac function over 12 months of imatinib treatment. Advancing age associated with 
reduced cardiac performance for patients receiving imatinib.
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INTRODUCTION
Imatinib has transformed the outlook for chronic myeloid leukemia 
(CML) and gastrointestinal stromal tumor. In CML, the majority 
of chronic phase patients remain well with complete cytogenetic 
responses after 8 years of treatment [1], with excellent quality of life, 
in sharp contrast to interferon alfa, the previous standard of care [2]. 
The 5-year survival rate is 90% with optimal therapy [3]. In 2008, the 
majority of patients diagnosed with chronic phase myeloid leukemia 
can expect to have durable responses with good quality of life. From 
20% to 30% of patients who fail for imatinib treatment, second-line 
treatments are an effective salvage strategy [4]. The first report of 
imatinib causing cardiac problems was in 2006, documenting ABL-
mediated impairment of cardiacmyocyte function in culture, and citing 
10 patients who developed cardiac failure while receiving imatinib [5]. 
This was clinically unanticipated and created considerable alarm among 
patients. However, most of these 10 patients had relevant comorbidities 
and most responded well to standard heart failure regimens [6].
In the pivotal phase III International Randomized Study of Interferon 
and STI571 (IRIS) trial, primary resistance observed in 24% of patients, 
and secondary resistance presented as relapse in 17% of patients and 
disease progression in 7% after 4.5 years [7]. After 6 years, 34% of 
patients had discontinued imatinib treatment, mostly (14%) because of an 
unsatisfactory therapeutic effect (defined as lack of efficacy/progression), 
but a number of patients (5%) also stopped receiving the drug as a result 
of adverse events (AEs) or abnormal laboratory values [8]. Although rare, 
severe congestive heart failure (CHF) and left ventricular dysfunction have 
reported during imatinib treatment, especially in patients with risk factors 
or comorbidities. In the IRIS trial, this observed in 0.7% of patients [7]. 
Cardiotoxicity associated with high-dose imatinib was not reported during 
the START-R study [9]. In a large review of patients enrolled in imatinib 
clinical studies (n=1.276), 1.8% of patients had symptoms suggestive of 
systolic heart failure. Most had risk factors for cardiac failure. In total, 0.6% 
of patients had cardiac events attributed to imatinib treatment [10].
The mechanism underlying imatinib-induced cardiac failure is currently 
unclear. In an in vitro study, physiological concentrations of imatinib 
significantly and adversely affected mitochondrial membrane potential, 
apoptosis, cell viability, and cellular ultrastructure [11]. This cardiotoxic 
effect may link to inhibition of BCR-ABL. Imatinib was reported to cause 
stress-induced and dose-dependent mitochondrial changes in murine 
ventricular myocytes, which reduced by re-engineering the imatinib 
molecule such that BCR-ABL inhibition was hampered [5]. We have 
therefore conducted a prospective assessment of cardiac function for 
CML patients on imatinib therapy.
Patients and methods
Between May 2008 and December 2009, 50 patients with CML treated 
at the National Center of Hematology; Al-Mustansiriya University 
included in this study. All patients received Imatinib (Gleevec®; Novartis 
Pharmaceuticals Corporation, New Jersey, USA) 400 mg/day. All patients 
gave informed written consent, and the study performed in accordance 
with Helsinki Declaration for clinical research, the study approved by 
the college of medicine - Mustansiriyah University. The criterion for 
entry into the study was a treatment for CML with imatinib at any dose 
for at least 12 months. Entry offered to all 50 eligible patients at our 
center. Two patients had subsequently lost hematological remission and 
were being treated either with an increased dose of imatinib to 600 or 
by adding hydroxyurea because of lack of second-generation tyrosine 
kinase inhibitor (dasatinib or nilotinib). All other patients required no or 
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minimal dose interruption. All patients subjected to a complete medical 
history including detailed cardiac history. Furthermore, all serious 
AEs in these patients were reviewed, with particular attention to that 
related to cardiac origin. These included shortness of breath, dyspnea, 
chest pain, arrhythmia, cardiac events, myocardial infarction, angina, 
pleural effusion, and peripheral edema. Physical examination, a 12-lead 
electrocardiogram (ECG) and echocardiography are done to all patients.
Echocardiography was used to accurately measure the cardiac 
ejection fraction (EF; normal range 0.55–0.71 at our center), together 
with indices of ventricular ejection and relaxation and to measure 
left ventricular internal diameter in diastole (LVIDd; normal value 
<5.8 cm) and in systole (LVIDs; normal value <4.5 cm), since left 
ventricular dilatation may be an early feature of heart failure. Second 
echocardiography performed after a further 12 months. Subgroup 
analysis was carried out according to gender, age, and duration of 
imatinib treatment. Independent t-test and one-way ANOVA with trend 
used to analyze the statistical significance, p≤0.05 was considered 
statistically significant, all analysis performed using GraphPad Prism 
7.0 software package.
RESULTS
Of the 50 patients evaluated, 24 (41%) were men and 26 (59%) were 
women. Their ages ranged from 18 to 74 years, with a median age of 
36.8 years. In 2 patients (4%), the time interval between the diagnosis 
of CML and the initiation of imatinib therapy was longer than 1 month; 
in 48 patients (96%), this time was 1 month or shorter. The mean 
duration of imatinib treatment before enrolment was 3.4±1.8 years. 
Pre-existing diagnoses relevant to the cardiovascular system included 
hypertension (4 patients), obesity (3 patients), smoking (2 patients), 
type 2 diabetes mellitus (1 patient), and angina (1 patient), all of which 
predated the diagnosis of CML.
Table 1: Treatment characteristics at study entry and during 
follow-up
Variables Value, n (%)
Treatment and dose at study entry
Imatinib 400 mg daily 44 (88)
Imatinib 600mg daily 6 (12)
Treatment changes during follow-up
Unchanged 48 (96)
Imatinib 400 daily to imatinib 600 1 (2)
Imatinib 400 daily to 
imatinib+hydroxyurea
1 (2)
Table 2: Subgroup analysis according to gender, age, and duration of treatment
Subgroups No. EF (mean±SD) LVIDd (mean±SD) LVIDs (mean±SD)
Age (years)
5–25 7 0.63±0.035 5.40±0.00 3.55±0.21
26–35 18 0.62±0.037 5.35±0.26 3.2±0.28
36–45 11 0.65±0.047 5.18±0.36 3.48±0.48
46–55 9 0.62±0.059 5.16±0.34 3.30±0.45
56–65 3 0.64±0.074 4.58±0.69 2.70±0.41
66–75 2 0.65±0.068 4.94±0.94 2.99±0.68
p value 50 0.535 0.015 [S.] 0.011 [s.]
Gender
Male 24 0.63±0.051 5.38±0.42 3.41±0.49
Female 26 0.64±0.063 4.83±0.58 2.99±0.47
p value 50 0.542 0.0004 [S.] 0.003 [S.]
Duration of imatinib treatment (years)
0–1 5 0.63±0.050 5.10±0.30 3.28±0.33
>1–2 5 0.65±0.075 4.73±0.90 2.90±0.62
>2–3 10 0.62±0.057 4.96±0.50 3.08±0.47
>3–4 10 0.63±0.061 5.23±0.47 3.23±0.62
>4–5 8 0.65±0.054 5.24±0.26 3.17±0.33
>5–6 8 0.63±0.061 5.42±0.57 3.48±0.59
>6–7 4 0.60±0.040 4.83±0.42 3.13±0.40
p value 50 0.454 0.464 0.491
LVIDd: Left ventricular internal diameter in diastole, LVIDs: Left ventricular internal diameter in systole
Fig. 1: Left ventricular internal diameter in diastole (LVIDd) and LVID in systole distribution according to age
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Resting ECG recordings taken at baseline were normal for 47 patients, 
three had voltage criteria for left ventricular hypertrophy, and two had 
evidence of limited previous myocardial infarction. Echocardiography 
identified aortic sclerosis in four and mitral valve prolapse in one 
participant. Two patients had baseline EF values on echocardiography 
that was below normal (<0.55). One of these patients had a history 
of mild dilated cardiomyopathy, documented by echocardiography, 
before the diagnosis of CML and initiation of imatinib treatment. This 
patient had a baseline EF of 0.52 and LVIDd of 6.8 cm. One patient with 
hypertensive heart disease had an EF of 0.48 and LVIDd of 5.7 cm. 
Neither of these patients showed any significant change in cardiac 
condition or imaging values during the 1-year follow-up (Table 1).
There significant inverse trend for both LVIDd and LVIDs reduced as age 
increase, the female had significantly lower LVIDd and LVIDs compared 
to male, as illustrated in Table 2 and Fig. 1.
DISCUSSION
At entry to the study, mean EF for the 50 patients was 0.63±0.057. Mean 
LVIDd was 5.09±0.58 cm after 12 months follow-up; mean EF obtained 
by echocardiography was 0.64±0.068, which is not significantly different 
from the mean baseline EF. Mean peak emptying rate at entry was 
3.23±0.5 ED/s, and after 1 year was 3.21±0.5 ED/s. Time to peak filling 
rate at entry was 144±26 ms, and after 1 year was 143±25 ms. There 
was no significant difference between any of the echocardiographic 
measurements when compared at baseline and after 1-year follow-
up. Our findings were in agreement with Druker et al., in which they 
reported only one patient (<1%) having CHF after a follow-up period 
of 60 months [7], and in agreement with a more recent study in which 
all patients after 1-year follow-up did not show cardiotoxicity [12]. In 
the current study advanced age appear to negatively influence cardiac 
function in which both LVIDd and LVIDs reduced significantly with 
advancing age, our findings were in agreement with Maharsy et al. 
study in which they found that imatinib-induced cardiotoxicity in rat 
is age-dependent [13], this effect of imatinib on cardiac cells mediated 
through the inhibition of cardiomyocyte cAbl and activation of the JunK 
pathway [13].
The present study has two findings that are reassuring to CML patients 
and their clinicians. First, in a prospective approach designed to 
detect evidence of myocardial dysfunction, we have found no proof 
of this except in patients with pre-existing cardiac problems. Second, 
an assessment with an interval of 12 months revealed no evidence of 
any deterioration in myocardial function, despite the continuation of 
imatinib. The present data, therefore, add to and extend the currently 
available data on cardiac function in patients receiving imatinib 
treatment. Using echocardiography, a sensitive indicator of left 
ventricular performance, we find no evidence of significant impairment 
in cardiac function over 12 months of imatinib treatment. The result of 
the current study is consistent with previous reports and will reassure 
CML patients and their physicians on the cardiac safety of imatinib. 
Imatinib remains a safe and invaluable drug that is rightly the gold 
standard of CML care. Studies should, therefore, continue whether it 
can sustain long-term disease control.
CONCLUSION AND RECOMMENDATION
There is no evidence of significant impairment in cardiac function 
over 12 months of imatinib treatment. Advancing age associated with 
reduced cardiac performance for patients receiving imatinib. We 
recommend studying the neopterin level in patients with thalassemia 
major patients with <1000 ng/ml, and it’s relation to the frequency of 
blood transfusion in major thalassemia patients.
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